Overview

Dexlansoprazole MR-Based Concomitant Quadruple Therapy

Status:
Completed
Trial end date:
2019-04-20
Target enrollment:
0
Participant gender:
All
Summary
Background: Recommended proton pump inhibitor (PPI)-clarithromycin-amoxicillin or metronidazole treatment for 7 to14 days is the first choice treatment for H pylori infection. The eradication rate of the standard triple therapy has generally declined to unacceptable levels (i.e., 80% or less) recently because the increasing incidence of clarithromycin-resistant strains of H. pylori. Standard triple therapies should be abandoned in the areas with clarithromycin resistance ≥ 20%. The investigators have proven that 7-day Concomitant therapy can achieve a promising success rate of >90 % in the presence of clarithromycin resistance. However, high dose PPI is needed with a dosage of twice daily but when a dual delayed release formulation PPI in capsules for oral administration (Dexlansoprazole MR), a once daily dose may be needed only. The capsules contain dexlansoprazole in a mixture of two types of enteric-coated granules with different pH-dependent dissolution profiles. It suppresses gastric acid secretion via inhibition of the proton pump in the gastric parietal cell, which blocks the final step of acid production. Thus, it improves acid suppression and offer benefits over conventional single release PPI formulations. by prolonging optimal plasma concentration and create a favorable condition H. pylori eradication Aim: The efficacy of Dexlansoprazole MR-based concomitant quadruple therapy
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Chang Gung Memorial Hospital
Treatments:
Amoxicillin
Clarithromycin
Dexlansoprazole
Lansoprazole
Metronidazole
Criteria
Inclusion Criteria:

H. pylori-infected outpatients with endoscopically proven peptic ulcer diseases or
gastritis.

Exclusion Criteria:

1. Previous H. pylori-eradication therapy

2. ingestion of antibiotics, bismuth, or PPIs within the prior 4 weeks

3. patients with allergic history to the medications used

4. patients with previous gastric surgery

5. the coexistence of serious concomitant illness (for example, decompensated liver
cirrhosis, uremia)

6. pregnant women.